First-in-man Study of the Cerebrovascular Interventional Procedural Control System

Inclusion Criteria: 1. Age 18-80. 2. Diagnosed with acute ischemic stroke. 3. Arterial occlusion in the anterior cerebral circulation that was confirmed by CTA or MRA. 4. Subject could be treated intraarterially within 8 hours after symptom onset. 5. Prestroke Modified Rankin Score ≤ 1. 6. National Institutes of Health Stroke Scale (NIHSS) ≥6 and ≤20. 7. Patients or their legally authorised representatives provided signed, informed consent. Exclusion Criteria: 1. NCCT ASPECT score \<6，or the infarct volume exceeded 1/3 of the middle cerebral artery blood supply area. 2. CT/MR Showed midline shift or cerebral hernia, and ventricle occupying effect. Intracranial hemorrhage. CTA/MRA shows carotid artery dissection, severe stenosis, or complete occlusion, which requiring carotid stent implantation during thrombectomy; Bilateral acute stroke or multiple intracranial large vessel occlusion. 3. Females who are pregnant or lactating. 4. Severe allergy to contrast agents, nickel-titanium metal or its alloys. 5. Drug-resistant hypertension (defined as sustained systolic blood pressure \>185mmHg or diastolic blood pressure \>110mmHg). 6. Hemorrhagic tendency (including but not limited to platelet \<100\*109/L, heparin treatment within 48 hours with APTT ≥35s, taking warfarin with an INR \> 1.7). 7. Surgery or biopsy of parenchymal organs within the last 1 month 8. Any active or recent bleeding (gastrointestinal, urinary, etc.) within the last 1 month 9. Undergoing hemodialysis or peritoneal dialysis; exist of severe renal insufficiency (serum creatinine \>220umol/L or 2.5mg/dl) 10. Previous intracranial hemorrhage, subarachnoid hemorrhage, brain tumor. 11. Life expectancy of less than 1 year. 12. Enrollment in another clinical trial evaluating other devices or drugs during the same period. 13. Abnormalities or diseases that the investigator considers to be excluded from the study's coverage.